Terms: = Prostate cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Diagnosis
16 results:
1. cdk12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
[TBL] [Abstract] [Full Text] [Related]
2. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract] [Full Text] [Related]
3. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant prostate cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract] [Full Text] [Related]
4. Somatic and Germline Variants Affect Prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
Jang A; Lanka SM; Huang M; Casado CV; Caputo SA; Sweeney PL; Gupta K; Pocha O; Habibian N; Hawkins ME; Lieberman AD; Schwartz J; Jaeger EB; Miller PJ; Layton JL; Barata PC; Lewis BE; Ledet EM; Sartor O
Prostate; 2023 Aug; 83(11):1028-1034. PubMed ID: 37113064
[TBL] [Abstract] [Full Text] [Related]
6. The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy.
Wang Y; Zhu Y; Fan L; Liu J; Pan J; Xue W
Int Urol Nephrol; 2023 Jun; 55(6):1447-1452. PubMed ID: 37017821
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic and clinicopathological value of cdk12 mutation in prostate cancer: a meta-analysis.
Zhang W; Zhou L; Di J
Expert Rev Anticancer Ther; 2023 Feb; 23(2):207-216. PubMed ID: 36734254
[TBL] [Abstract] [Full Text] [Related]
8. MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
Zeng Z; He W; Jiang Y; Jiang H; Cheng X; Deng W; Zhou X; Zhang C; Wang G
BMC Cancer; 2022 Nov; 22(1):1162. PubMed ID: 36357836
[TBL] [Abstract] [Full Text] [Related]
9. Characterizing cyclin-dependent kinase 12(cdk12)-altered aggressive prostate cancer: a twelve-case series.
Iwasawa T; Kosaka T; Yasumizu Y; Hongo H; Yanai Y; Baba Y; Matsumoto K; Nakamura K; Nishihara H; Oya M
Int J Clin Oncol; 2022 Dec; 27(12):1867-1873. PubMed ID: 36271301
[TBL] [Abstract] [Full Text] [Related]
10. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive prostate cancer.
Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
[TBL] [Abstract] [Full Text] [Related]
11. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
12. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive prostate cancer.
Freeman MN; Jang A; Zhu J; Sanati F; Nandagopal L; Ravindranathan D; Desai A; Phone A; Nussenzveig R; Jaeger E; Caputo SA; Koshkin VS; Swami U; Basu A; Bilen MA; Agarwal N; Sartor O; Burgess EF; Barata PC
Oncologist; 2022 Mar; 27(3):220-227. PubMed ID: 35274720
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of cdk12 alterations in a pan-cancer database.
Pan E; Cabal A; Javier-DesLoges J; Patel D; Panian J; Lee S; Shaya J; Nonato T; Xu X; Stewart T; Rose B; Shabaik A; Cohen E; Kurzrock R; Tamayo P; McKay RR
Cancer Med; 2022 Feb; 11(3):753-763. PubMed ID: 34898046
[TBL] [Abstract] [Full Text] [Related]
14. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract] [Full Text] [Related]
15. Characterizing cdk12-Mutated prostate cancers.
Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS
Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971
[TBL] [Abstract] [Full Text] [Related]
16. Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J; Seed G; Bertan C; Rescigno P; Dolling D; Figueiredo I; Miranda S; Nava Rodrigues D; Gurel B; Clarke M; Atkin M; Chandler R; Messina C; Sumanasuriya S; Bianchini D; Barrero M; Petermolo A; Zafeiriou Z; Fontes M; Perez-Lopez R; Tunariu N; Fulton B; Jones R; McGovern U; Ralph C; Varughese M; Parikh O; Jain S; Elliott T; Sandhu S; Porta N; Hall E; Yuan W; Carreira S; de Bono JS
J Clin Invest; 2020 Apr; 130(4):1743-1751. PubMed ID: 31874108
[TBL] [Abstract] [Full Text] [Related]